News

Drug Discovery World | Are scalable data science platforms the way forward?

Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.

whitepages icon x

Manufacturing Chemist | The increasing power of single-cell omics: changing the future of medicine

Advances in the single-cell genomic analysis of cells and tissues, including the required computational methods, have now put systematic, high-resolution and comprehensive reference maps of all human cells within our reach. Paradigm4’s Marilyn Matz, CEO and cofounder, and Dr Zachary Pitluk, VP of Life Sciences and Healthcare, report

whitepages icon x

WALTHAM, Mass. || Paradigm4, Inc. announces the general availability of flexFS

Paradigm4 announces the general availability of flexFS, a hyperscale file system designed for AI/ML and large file data workloads, providing unparalleled throughput at 50% lower cost

whitepages icon x

LABIOTECH || Partnership between Paradigm4 and Alnylam accelerates drug target discovery

New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.